JMP Securities downgraded T-cell therapy developer Adicet Bio (NASDAQ:ACET) to market perform and removed its price target of $19, citing uncertainty about the start date for a pivotal study for the ...

On Tuesday, JMP Securities sustained their Market Outperform rating for AN2 Therapeutics (NASDAQ:ANTX) shares, with a ...

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc.

On Wednesday, JMP Securities adjusted its share price target for Crinetics Pharmaceuticals (NASDAQ:CRNX), increasing it to $80 from the previous $60, while maintaining a Market Outperform rating. This ...

Investing.com - Citizens JMP has reiterated its Market Outperform rating and $5.00 price target on Teads Holding (NASDAQ:TEAD), a digital advertising company with a market capitalization of $160.5 ...

Citizens JMP raised the firm’s price target on Nuvation Bio (NUVB) to $10 from $8 and keeps an Outperform rating on the shares. Safusidenib, in a Phase 2 Japanese glioma study, significantly ...